# Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular Carcinoma

> **NCT06571396** · — · RECRUITING · sponsor: **Qilu Hospital of Shandong University** · enrollment: 200 (estimated)

## Conditions studied

- Carcinoma, Hepatocellular
- Immunotherapy

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06571396
- **Lead sponsor:** Qilu Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2014-04-01
- **Primary completion:** 2025-08-01
- **Final completion:** 2026-08-03
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06571396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06571396, "Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06571396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*